Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
Read More

FDA Has Granted Breakthrough Therapy Designation To Moderna’s Respiratory Syncytial Virus Vaccine Candidate, mRNA-1345

The designation is based on topline data from the ConquerRSV Phase 3 efficacy trial, which demonstrated vaccine efficacy of 83.7% against RSV lower respiratory tract disease.The designation is based on topline data from the ConquerRSV Phase 3 efficacy trial, which demonstrated vaccine efficacy of 83.7% against RSV lower respiratory tract disease.

MRNA

Read More

Kane Biotech’s Coactiv+™ Technology Could Address a Pricey and Painful Problem: Lack of Healing in Chronic Wounds Due to Microbial Biofilm Formation

Chronic wounds are a persistent and pricey problem for patients and health care systems around the world. Defined as “wounds that fail to proceed through the normal phases of wound healing in an orderly and timely manner,” chronic wounds range from severe burns to bedsores to diabetic ulcers. 

KNBIF